Holen Sie sich die Stockscreener-App
1.99
0.51%
0.01
Handel nachbörslich:
2.02
0.03
+1.51%
Schlusskurs vom Vortag:
$1.98
Offen:
$1.95
24-Stunden-Volumen:
401.34K
Relative Volume:
0.24
Marktkapitalisierung:
$4.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.91M
KGV:
-0.6104
EPS:
-3.26
Netto-Cashflow:
$-6.14M
1W Leistung:
+8.74%
1M Leistung:
+9.94%
6M Leistung:
-32.10%
1J Leistung:
-46.16%
1-Tages-Spanne:
$1.79
$2.09
1-Wochen-Bereich:
$1.61
$2.09
52-Wochen-Spanne:
$1.15
$23.80
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Firmenname
Galmed Pharmaceuticals Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GLMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
1.99 | 4.47M | 0 | -6.91M | -6.14M | -3.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-05-22 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2020-02-04 | Eingeleitet | Craig Hallum | Buy |
| 2020-01-30 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-12-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-08-02 | Bestätigt | Maxim Group | Buy |
| 2018-07-13 | Eingeleitet | Stifel | Buy |
| 2018-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-06-12 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2018-02-14 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-15 | Eingeleitet | ROTH Capital | Buy |
| 2017-08-08 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Bestätigt | Maxim Group | Buy |
| 2016-08-01 | Bestätigt | Maxim Group | Buy |
| 2016-07-06 | Fortgesetzt | ROTH Capital | Buy |
| 2016-03-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-05-06 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
Alle ansehen
Galmed Pharmaceuticals Ltd Aktie (GLMD) Neueste Nachrichten
What drives Galmed Pharmaceuticals Ltd. stock priceExceptional profit potential - PrintWeekIndia
Galmed Pharmaceuticals to Hold Special Meeting on Share Capital Increase - TipRanks
What analysts say about Galmed Pharmaceuticals Ltd. stockFree Stock Market Beginners Guide - Autocar Professional
Galmed Pharmaceuticals Ltd. Stock Analysis and ForecastMarket-crushing stock picks - Autocar Professional
Is Galmed Pharmaceuticals Ltd. a good long term investmentTurbocharged investment results - jammulinksnews.com
The Role of News and Events in Galmed Pharmaceuticals Ltd Inc. (GLMD) Price Performance - investchronicle.com
Why India’s Pharmaceutical Stocks Are on the Rise High Accuracy Trade SignalsRapid market gains - PrintWeekIndia
Solara Active Pharma Sciences Limited (SOLARAPP)’s Trend in 2025Free Stock Market Forecast Reports - jammulinksnews.com
PLAB Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com
What makes Galmed Pharmaceuticals Ltd. stock price move sharplyFree Insider Trading Tips - Newser
Why Galmed Pharmaceuticals Ltd. stock attracts strong analyst attentionSafe and Scalable Investment Tips - Newser
How Galmed Pharmaceuticals Ltd. stock performs during market volatilitySteady Profit Stock Forecasts - Newser
Galmed Pharmaceuticals Ltd. to Host Earnings Call - ACCESS Newswire
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond Nash - marketscreener.com
Galmed Pharmaceuticals Unveils Biomarker Signature for Aramchol, Expanding Market Potential - TipRanks
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH - Longview News-Journal
Wall Street Zen Upgrades Galmed Pharmaceuticals (NASDAQ:GLMD) to Sell - Defense World
Galmed Pharmaceuticals: Q1 Earnings Snapshot - New Haven Register
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Galmed Pharmaceuticals Reports Q1 2025 Financial Results and Advances in Oncology - TipRanks
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World
Galmed Pharmaceuticals Unveils Promising Aramchol Results in PSC Models - TipRanks
Galmed (GLMD) Announces Promising Pre-Clinical Results for Aramc - GuruFocus
Finanzdaten der Galmed Pharmaceuticals Ltd-Aktie (GLMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):